ভাৰতত GLP-1 Therapy-এর বাবে কে Qualify?
GLP-1 eligibility simple BMI checklist নহয়। ICMR RSSDI South Asian earlier metabolic risk thin-fat phenotype, central obesity, young age family diabetes account। criteria doctor use informed consultation prepare, decline why understand, self-diagnose unregulated seller prescription guarantee avoid। documentation honest lifestyle history scale number equally matter। diabetes obesity pathway contraindication screening CDSCO Schedule H nationwide equally apply।
Short answer
India GLP-1 RA RSSDI first-line insufficient type 2 diabetes; obesity BMI ≥27.5 kg/m² বা prediabetes/hypertension/fatty liver comorbidity-সহ ≥25 ICMR। obesity pharmacotherapy lifestyle trial precedes। contraindication, affordability, monitoring capacity physician assess—Kesho qualification determine/guarantee নহয়। specialist visit lab, waist, lifestyle documentation bring।
Key takeaways
- •Type 2 diabetes indication high BMI not required—RSSDI metformin lifestyle HbA1c target unmet GLP-1 RA support।
- •Obesity ICMR-aligned BMI ≥27.5, comorbidity-সহ ≥25—Western BMI ≥30 lower।
- •Waist (>90 cm men, >80 cm women) thin-fat phenotype South Asian BMI equally matter।
- •Pregnancy, MTC/MEN2 history, severe pancreatitis contraindication—BMI regardless CDSCO label।
- •Obesity pharmacotherapy 3–6 month lifestyle intervention precedes; GLP-1 cosmetic shortcut never।
Type 2 diabetes-এ GLP-1 therapy qualify?
RSSDI GLP-1 RA important option lifestyle metformin glycaemic target fail typically HbA1c 7–7.5% above optimised care। particularly established cardiovascular disease, heart failure, CKD, obesity, sulfonylurea hypoglycaemia risk favour। single BMI cut-off diabetes indication নহয়; lean Indian type 2 overall cardiovascular renal risk GLP-1 RA। age kidney concurrent medicine selection influence। type 1 gestational without specialist diabetic ketoacidosis not indicated। diabetologist/endocrinologist HbA1c trend fasting post-meal glucose complication screening class recommend। CDSCO product Schedule H prescription clinical criteria clear equally require।
India obesity criteria GLP-1?
Obesity pharmacotherapy ICMR national guideline South Asia adapted BMI ≥27.5 kg/m² without comorbidity medication consider, BMI ≥25 comorbidity present। Western BMI ≥30 below threshold Indians insulin resistance fatty liver cardiovascular risk lower weight। waist men 90 cm+ women 80 cm+ South Asian BMI supplement clinical assessment। pharmacotherapy never first-line structured lifestyle three-six months follow। motivation mental health eating disorder history long-term therapy afford assess before prescribe। cosmetic motivation metabolic indication appropriate prescribing নহয়। BMI threshold structured lifestyle attempt defer dietitian refer first।
- Thin-fat phenotype
- South Asian common pattern: apparently normal BMI high visceral fat low muscle mass early metabolic disease associate।
Indian BMI threshold Western guideline differ কেন?
Asian Indian phenotype Joshi et al. literature higher visceral adiposity greater insulin resistance earlier type 2 diabetes Caucasian same BMI। Chennai BMI 26 European BMI 28 metabolic risk higher। RSSDI ICMR incorporate realities। clinical judgement essential: marathon vegetarian BMI 27 no comorbidity differ sedentary executive BMI 27 prediabetes fatty liver manage। genetic family history socioeconomic population guideline fully capture individual decision। WHO Asian BMI cut-off underpin ICMR India-specific most directly relevant patient document।
BMI thresholds: Western vs India-aligned
| Context | Western obesity cut-off | India-aligned threshold |
|---|---|---|
| Pharmacotherapy without comorbidity | Often BMI ≥30 | Often BMI ≥27.5 (ICMR) |
| Pharmacotherapy with comorbidity | Often BMI ≥27 | Often BMI ≥25 with comorbidity |
| Waist circumference focus | Less emphasised | Central obesity central to risk |
| Lifestyle trial first | Recommended | Required 3–6 months (ICMR) |
| Type 2 diabetes indication | Glycaemic criteria | RSSDI: after metformin if uncontrolled |
Common comorbidity earlier GLP-1 consideration support (BMI ≥25)
| Comorbidity | Why it matters |
|---|---|
| Prediabetes / elevated HbA1c | Reduces progression to diabetes; improves insulin sensitivity |
| Hypertension | Weight loss and glycaemic control support blood pressure management |
| Dyslipidaemia | GLP-1 RAs may improve triglycerides and weight-related lipid changes |
| NAFLD / fatty liver | Weight loss of 5–10% can reduce hepatic steatosis |
| Obstructive sleep apnoea | Weight reduction improves apnoea severity in many patients |
| Established cardiovascular disease | RSSDI favours GLP-1 RAs in high-risk diabetes patients |
Comorbidity GLP-1 therapy case strengthen?
BMI beyond metabolic condition cluster weigh। central obesity prediabetes multiple agent hypertension high triglyceride ultrasound NAFLD obstructive sleep apnoea each lifestyle alone insufficient pharmacotherapy justification add। PCOS insulin resistance endocrine discussion frequent। premature cardiovascular disease diabetes family history borderline number risk framing strengthen। RSSDI cardiovascular integration diabetes heart disease GLP-1 RA algorithm earlier isolated mild obesity patient। lab imaging self-report alone document। ICMR obesity chronic disease complication treat cosmetic issue emphasise।
Qualify না বা specialist review?
Contraindication pregnancy breastfeeding MTC/MEN2 severe prior pancreatitis। severe gastroparesis active IBD frail elderly low BMI further weight loss harmful caution। inadequately treated eating disorder psychiatric support before appetite-suppressing medicine। monitoring afford sustained therapy unable alternative counsel। first-degree thyroid cancer history careful endocrine evaluation। Kesho screen eligibility determine নহয়—only treating physician full history examination investigation decide। CDSCO product label contraindication BMI regardless legally binding।
Medically reviewed
Dr. Ananya Mehta, MD, DM Endocrinology
Consultant Endocrinologist, India
This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.
Last medically reviewed: Jun 26, 2026